ClinicaliQ Trial Snapshot
- A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn’s Disease — Recruiting • Phase III • Gastroenterology • NCT07298421.
- Trial testing a new drug (Afimkibart) for treating moderate-to-severe Crohn's disease in children.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD). Conditions: Moderately to Severely Active Crohns Disease Interventions: Afimkibart Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 100 participants